Leidos Selects Tempus to Help Collate, Summarize NCI Clinical Data

Jeff Brody

Leidos’ biomedical research business has tapped Tempus to collate and summarize follow-up clinical data for a National Cancer Institute project that aims to provide data that will contribute to improved cancer diagnosis and treatment.

Tempus said Tuesday it has collaborated with Leidos to secure and consolidate updated medical records from 230 contributors as part of the Cancer Genome Atlas program.

Utilizing its Tempus O system, the company will filter and summarize the collected clinical data prior to their alignment with molecular information. NCI plans to release the completed dataset publicly for researchers’ usage.

“We are pleased to support the NCI and the many medical centers whose investigators have contributed to TCGA, and we are eager to integrate these important datasets in pursuit of research and improved patient care," said Kevin White, president at Tempus.

Jointly established by NCI and the National Human Genome Research Institute in 2006, the TCGA initiative has categorized more than 20K cancer and matched normal samples and validated 33 different cancer types.

You may also be interested in...


Air Force Taps SpaceX to Investigate High-Capacity Manufacturing Tech for Thermal Protection Systems

Air Force Research Laboratory has awarded an $8.5 million contract to SpaceX to enhance manufacturing technologies used to produce hypersonic-capable thermal protection systems, Space News reported Monday.

AlertTrace by VOS Systems

USAF Procures Contact Tracing Tech From VOS Systems for COVID-19 Response Efforts

VOS Systems received a contract of an undisclosed sum from the U.S. Air Force to deliver, field and sustain an electronic COVID-19 contact tracing tool.

5G technology

VA Hospital Adopts T-Mobile 5G Platform; David Bezzant Quoted

T-Mobile has helped the Department of Veterans Affairs implement 5G technology at a hospital in Miami to support care delivery and telehealth services through instant mobile connectivity.